GUTS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Fractyl Health Inc (GUTS) does not present a compelling buy opportunity for a beginner investor with a long-term strategy at this time. The stock's technical indicators are neutral, the financial performance is weak, and there are no strong positive catalysts or trading signals to justify immediate investment.
The MACD is slightly positive but contracting, RSI is neutral at 63.295, and moving averages are converging. The stock is trading near its resistance level (R1: 0.526) but lacks strong momentum. Key support is at 0.482.
Analysts from H.C. Wainwright maintain a Buy rating with an optimistic outlook for the pivotal REMAIN-1 readout in Q4, which could position Revita as a significant solution for patients discontinuing GLP-1 therapy.
Morgan Stanley downgraded the stock to Equal Weight, citing disappointing weight-regain data from the REMAIN-1 midpoint cohort. BofA also lowered its price target, reflecting cautious sentiment. Additionally, the company's financials show no revenue and significant losses.
In Q3 2025, revenue dropped to 0 (-100% YoY), net income improved to -$45.6M (+96.79% YoY), EPS increased to -0.71 (+47.92% YoY), and gross margin dropped to 0 (-100% YoY). The company is not generating revenue and remains deeply unprofitable.
Mixed ratings: H.C. Wainwright maintains a Buy with a price target of $8, while BofA and Morgan Stanley have reduced price targets to $2. Analysts are cautious due to underwhelming trial data but see potential in future pivotal results.
